Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Fineline Cube Jun 8, 2026
Company Deals

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Fineline Cube Jun 8, 2026
Company Deals

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Fineline Cube Jun 8, 2026
Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Fineline Cube Jun 8, 2026
Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Fineline Cube Jun 8, 2026
Company Policy / Regulatory

Taiwan’s TFDA Orders Recall of Two Nucala Batches Due to Glass Fragments

Fineline Cube Jul 25, 2023

The Food and Drug Administration (FDA) bureau of Taiwan, part of Greater China, has issued...

Company Drug

Eli Lilly’s Mirikizumab and Chia Tai Tianqing’s Lanifibranor Enter Breakthrough Therapy Review

Fineline Cube Jul 25, 2023

US pharmaceutical major Eli Lilly’s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing’s lanifibranor have...

Company Deals

Amoy Diagnostics and AstraZeneca Expand Partnership for Companion Diagnostic Development

Fineline Cube Jul 25, 2023

China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced an additional cooperation agreement with...

Company Drug

Vcanbio’s VUM02 Stem Cell Therapy Accepted for Review by China’s CDE for aGvHD Treatment

Fineline Cube Jul 25, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the Center...

Medical Device Policy / Regulatory

NMPA Updates List of Medical Devices Exempt from Clinical Evaluation in China

Fineline Cube Jul 25, 2023

The National Medical Products Administration (NMPA) has released an updated version of the “List of...

Policy / Regulatory

Chinese Health Authorities Unveil Key Reform Tasks for Medical System in H2 2023

Fineline Cube Jul 25, 2023

The National Health Commission (NHC), National Development and Reform Commission (NDRC), Ministry of Finance (MoF),...

Policy / Regulatory

NHSA Releases Official Guidelines for Drug Negotiations and Bidding for NRDL Update

Fineline Cube Jul 24, 2023

The National Healthcare Security Administration (NHSA) has officially released the “Negotiation Drug Renewals” and “Non-exclusive...

Company Deals

Carbon Medical Technology Secures Over RMB 100 Million in Series A Financing for Interventional Therapy

Fineline Cube Jul 24, 2023

Shenzhen-based Carbon Medical Technology Co., Ltd has reportedly raised over RMB 100 million (USD 13.9...

Company Drug

BeiGene’s Tislelizumab Receives Positive CHMP Opinion for Esophageal Cancer Treatment

Fineline Cube Jul 24, 2023

BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received a...

Company Drug

CanSino Biologics Granted Approval by Health Canada for Zoster Vaccine Candidate CS-2032

Fineline Cube Jul 24, 2023

China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced receiving approval from Health Canada...

Company Deals Drug

Bavarian Nordic’s RSV Vaccine Candidate Fails Phase III Trial, Discontinues Program

Fineline Cube Jul 24, 2023

Denmark-based Bavarian Nordic A/S (CPH: BAVA) has revealed that its pipeline respiratory syncytial virus (RSV)...

Legal / IP Policy / Regulatory

National Health Commission Launches One-Year Anti-Corruption Campaign in Pharmaceutical Sector

Fineline Cube Jul 24, 2023

The emergency response department of the National Health Commission (NHC) has released a notification signaling...

Company

FDA Assures No Disruption to US Drug Supply Chain After Pfizer Warehouse Tornado

Fineline Cube Jul 24, 2023

The US Food and Drug Administration (FDA) has issued a statement this week, ruling out...

Company Deals

Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies

Fineline Cube Jul 21, 2023

China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license...

Company Drug

Antengene Corp. Receives FDA Fast-Track Designation for Xpovio in Myelofibrosis Treatment

Fineline Cube Jul 21, 2023

China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving fast-track designation from the US...

Company Deals

Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program

Fineline Cube Jul 21, 2023

US-based Riparian Pharmaceuticals, Inc., a biotechnology company focused on cardiovascular diseases and co-incubated by Viva...

Company Deals

Acotec Scientific and Boston Scientific Announce Comprehensive Collaboration Agreement

Fineline Cube Jul 21, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced a cooperation framework and service framework...

Company Drug

Hansoh Pharmaceutical’s Ibrexafungerp NDA Accepted for Review by China’s NMPA for VVC Treatment

Fineline Cube Jul 21, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that the National Medical Products...

Company Drug

GenScript Biotech’s CAR-T Therapy Carvykti Reports USD 117 Million in Sales

Fineline Cube Jul 21, 2023

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...

Company

SCG Cell Therapy Launches Global Manufacturing and R&D Center in Singapore with Automated System

Fineline Cube Jul 21, 2023

Singapore-based SCG Cell Therapy Pte. Ltd has announced the initiation of its global manufacturing and...

Posts pagination

1 … 512 513 514 … 679

Recent updates

  • PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset
  • Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence
  • Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States
  • Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy
  • Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Company Medical Device

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.